ES2531040T3 - Formas sólidas y procedimiento de preparación - Google Patents

Formas sólidas y procedimiento de preparación Download PDF

Info

Publication number
ES2531040T3
ES2531040T3 ES10775401T ES10775401T ES2531040T3 ES 2531040 T3 ES2531040 T3 ES 2531040T3 ES 10775401 T ES10775401 T ES 10775401T ES 10775401 T ES10775401 T ES 10775401T ES 2531040 T3 ES2531040 T3 ES 2531040T3
Authority
ES
Spain
Prior art keywords
solid forms
preparation procedure
formula
procedure
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10775401T
Other languages
English (en)
Inventor
Robin Clark
Doug Fry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corcept Therapeutics Inc
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43069047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2531040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of ES2531040T3 publication Critical patent/ES2531040T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Disintegrating Or Milling (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Forma sólida amorfa de un compuesto de Fórmula I:**Fórmula**
ES10775401T 2009-05-12 2010-05-11 Formas sólidas y procedimiento de preparación Active ES2531040T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17748309P 2009-05-12 2009-05-12
PCT/US2010/034382 WO2010132445A1 (en) 2009-05-12 2010-05-11 Solid forms and process for preparing

Publications (1)

Publication Number Publication Date
ES2531040T3 true ES2531040T3 (es) 2015-03-10

Family

ID=43069047

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10775401T Active ES2531040T3 (es) 2009-05-12 2010-05-11 Formas sólidas y procedimiento de preparación

Country Status (10)

Country Link
US (2) US8461172B2 (es)
EP (1) EP2429529B1 (es)
JP (1) JP5637568B2 (es)
CN (1) CN102421437B (es)
AU (1) AU2010247766B2 (es)
CA (1) CA2761255C (es)
DK (1) DK2429529T3 (es)
ES (1) ES2531040T3 (es)
IL (1) IL216305A0 (es)
WO (1) WO2010132445A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005222421B2 (en) * 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
CN103298343A (zh) * 2011-01-07 2013-09-11 科赛普特治疗公司 类固醇和糖皮质激素受体拮抗剂组合疗法
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP4219494B1 (en) 2013-11-25 2026-03-25 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
US10610534B2 (en) 2015-03-30 2020-04-07 Corcept Therapeutics, Inc. Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency
KR20180052120A (ko) 2015-08-13 2018-05-17 코어셉트 쎄라퓨틱스, 잉크. Acth-의존성 쿠싱 증후군을 감별 진단하는 방법
KR102197526B1 (ko) 2016-01-19 2020-12-31 코어셉트 쎄라퓨틱스 인코포레이티드 이소성 쿠싱 증후군의 감별 진단
MX390517B (es) 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
WO2018165460A1 (en) 2017-03-09 2018-09-13 Corcept Therapeutics, Inc. Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors
SG11201908790PA (en) 2017-03-31 2019-10-30 Corcept Therapeutics Inc Glucocorticoid receptor modulators to treat cervical cancer
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
AU2019404026B2 (en) 2018-12-19 2023-06-08 Corcept Therapeutics Incorporated Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
WO2020132046A1 (en) 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3131263C (en) 2019-02-22 2024-01-02 Corcept Therapeutics Incorporated Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
CN114650820A (zh) 2019-10-16 2022-06-21 科赛普特治疗学股份有限公司 通过选择性糖皮质激素受体拮抗剂使癌症患者的中性粒细胞对淋巴细胞比例正常化的方法
US11903945B2 (en) 2019-12-11 2024-02-20 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
WO2021154750A1 (en) 2020-01-29 2021-08-05 Corcept Therapeutics Incorporated TREATMENT OF ADRENOCORTICAL CARCINOMA WITH SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS (SGRMs) AND ANTIBODY CHECKPOINT INHIBITORS
KR20230017829A (ko) 2020-05-27 2023-02-06 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c8과 cyp3a4의 이중 기질인 파클리탁셀의 병용 투여
WO2022134033A1 (en) 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12616698B2 (en) 2021-05-05 2026-05-05 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2024077169A1 (en) 2022-10-06 2024-04-11 Corcept Therapeutics Incorporated Formulations of glucocorticoid receptor modulators
US12433882B2 (en) 2022-10-28 2025-10-07 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
AU2004270154A1 (en) * 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
AU2005222421B2 (en) * 2004-03-09 2010-09-23 Corcept Therapeutics, Inc. Fused ring azadecalin glucocorticoid receptor modulators
AR052918A1 (es) * 2005-02-25 2007-04-11 Recordati Ireland Ltd Clorhidrato de lercanidipina amorfo

Also Published As

Publication number Publication date
US8461172B2 (en) 2013-06-11
CA2761255C (en) 2017-05-09
AU2010247766A1 (en) 2011-11-24
CA2761255A1 (en) 2010-11-18
AU2010247766B2 (en) 2015-05-21
CN102421437B (zh) 2014-03-19
EP2429529A4 (en) 2012-11-07
IL216305A0 (en) 2012-01-31
DK2429529T3 (en) 2015-03-09
WO2010132445A1 (en) 2010-11-18
EP2429529A1 (en) 2012-03-21
US8889867B2 (en) 2014-11-18
JP5637568B2 (ja) 2014-12-10
US20130245266A1 (en) 2013-09-19
JP2012526826A (ja) 2012-11-01
US20100292477A1 (en) 2010-11-18
EP2429529B1 (en) 2015-01-14
CN102421437A (zh) 2012-04-18

Similar Documents

Publication Publication Date Title
CR20120121A (es) Compuestos de benzoxazepina como inhibidores de la pi3k y métodos de uso
CR20120348A (es) Nuevos compuestos tricíclicos
PL3812360T3 (pl) Związki monochlorotrifluoropropenu oraz kompozycje i sposoby ich zastosowania
DOP2012000114A (es) Inhibidor bromodominio de benzodiazepina
EP2485589A4 (en) HETEROARYL-BTK INHIBITORS
HUE040355T2 (hu) Benzilbenzol SGLT2-inhibitor kristályformája
BR112012005237A2 (pt) utilização de composições ternárias
IL225867B (en) Coelenterazine substrates
BR112012006686A2 (pt) composto amida substituído
EP2630614A4 (en) ADVANCED FUNCTIONALITY OF DEVICES WITH REMOTE ACCESS
DK2262793T3 (da) Krystallinske former af nilotinib-hci
EP2742051A4 (en) AMORPHIC FORM OF DOLUTEGRAVIR
HUE035861T2 (hu) Egy pleuromutilin kristályos formája
BR112012000890A2 (pt) formas de base livre cristalina de um composto bifenil
CR20120513A (es) HETEROARIL-CICLOHEXIL-TETRAAZABENZO [e] AZULENOS
PL2493466T3 (pl) Nowe przeciwguzowe zastosowanie kabazytakselu
AP3659A (en) A novel formulation of meloxicam
EP2561123A4 (en) ELECTROCHEMICAL SYNTHESIS OF AN ARYL-ALKYL-TENSID PRECURSOR
BR112012002268A2 (pt) fotoestabailização de retinóides com compostos de alcóxicrileno
FI20095644A0 (fi) Ulokkeen muodostaminen
CO6801700A2 (es) Uso demetilhidroxietilcvelulosacomo aditivo de cemento
DK2506840T3 (da) Anvendelser af hæmmere af hypoksi-fremkaldende faktorer
DK2453858T3 (da) Fremgangsmåde
EP2554608A4 (en) METAL PIGMENT COMPOSITION
DK2516435T3 (da) Inhibitorer af AKT-aktivitet